Problem

Healthcare organizations are struggling to maintain high-quality patient contact as workforce shortages, rising demand, and operational complexity increase. Routine follow-up by phone is labor-intensive, while app- and text-based programs often exclude older or less digitally engaged patients. The economics are especially painful in chronic disease: in Spain, a COPD hospitalization costs roughly €3,000–€5,000, and recurring exacerbations, emergency visits, and readmissions consume substantial clinical capacity and healthcare spending.

Tucuvi’s central use case is automating high-volume clinical follow-up after discharge and during chronic-disease management, with COPD and heart failure as particularly compelling examples. In one reported COPD deployment, LOLA was associated with a 19.6% reduction in hospitalizations, a 20.6% reduction in emergency visits, elimination of 30-day readmissions, and 90% adherence to follow-up calls. The broader value proposition is to identify deterioration earlier, avoid expensive acute care, and let nurses focus on complex cases rather than repetitive outreach.

Product / Service

Tucuvi provides an AI Care Management platform centered on LOLA®, a clinically validated voice AI agent that conducts autonomous, human-like phone conversations. Organizations configure evidence-based care protocols, such as symptom and medication checks for COPD, post-discharge monitoring for heart failure, or post-surgical follow-up. LOLA can make outbound calls, answer inbound calls, capture structured clinical information, and use a dashboard to stratify patients, generate summaries, manage tasks, and alert clinicians when an issue requires human intervention.

The delivery model is enterprise healthcare software that can start without an EHR integration and then connect through secure file exchange or bi-directional API/FHIR integrations. The platform handles workflow logic, documentation, escalation, and reporting, while a human-in-the-loop safety model routes anomalies to clinical teams. Because patients interact through ordinary phone calls without an app, internet connection, or new device, Tucuvi aims to improve reach while reducing nursing call time; the company has reported freeing up 70% of nursing-team time in follow-up programs.

Market

Tucuvi competes in the overlapping categories of clinical voice AI, AI-enabled care management, remote patient monitoring, patient engagement, and healthcare workflow automation. Its competitive set is therefore broader than a single direct peer group: software directories place it alongside patient-communication and RPM products such as Artera, Epic, Weave, and League, while healthcare-native voice-AI comparisons include Hippocratic AI, Notable, Infinitus, and Sully AI. Tucuvi differentiates itself through clinical protocols, autonomous care workflows, human escalation, healthcare integrations, and European medical-device regulation rather than simple appointment or contact-center automation.

The company is clearly in commercial deployment rather than pre-revenue experimentation. As of its January 2026 Series A announcement, Tucuvi said more than 60 organizations—including health systems, payers, and life-sciences companies—used the platform, which supported more than 50 workflows. Its site also reports more than one million autonomous voice-AI calls, while case studies describe large-scale deployments such as 868,000 calls at a 77% autonomy rate. Tucuvi raised $20 million in Series A funding led by Cathay Innovation and Kfund’s Leadwind, with plans to expand across Europe and the United States; revenue figures were not disclosed in the available research.